Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis

PHASE2CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

July 30, 2019

Study Completion Date

July 31, 2019

Conditions
DermatomyositisPolymyositis
Interventions
DRUG

tocilizumab

given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).

DRUG

placebo

given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).

Trial Locations (7)

11021

North Shore Long Island Jewish Center, Great Neck

15261

University of Pittsburgh, Pittsburgh

37235

Vanderbilt University, Nashville

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

66160

University of Kansas Medical Center, Kansas City

90048

Cedars Sinai Medical Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Chester Oddis

OTHER

NCT02043548 - Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | Biotech Hunter | Biotech Hunter